Incyte stock tumbled below its 200-day line Tuesday after sales of the company’s new skin treatment lagged the Street’s second-quarter expectations. X During the June quarter, Opzelura gen...
Incyte stock tumbled below its 200-day line Tuesday after sales of the company’s new skin treatment lagged the Street’s second-quarter expectations. X During the June quarter, Opzelura gen...